Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Roles for Paraoxonase but not Ceruloplasmin in Peritoneal Washing Fluid in Differential Diagnosis of Gynecologic Pathologies

  • Yildirim, Mustafa (Department of Medical Oncology, Ministry of Health Batman Regional Govermant Hospital) ;
  • Demirpence, Ozlem (Department of Biochemistry, Ministry of Health Batman Regional Govermant Hospital) ;
  • Kaya, Vildan (Department of Radiation Oncology, Suleyman Demirel University) ;
  • Suren, Dinc (Department of Pathology, Antalya Education and Research Hospital) ;
  • Karaca, Mehmet (Department of Obstetrics and Gynecology, Antalya Education and Research Hospital) ;
  • Evliyaoglu, Osman (Department of Biochemistry, Ministry of Health Batman Regional Govermant Hospital) ;
  • Yilmaz, Necat (Department of Biochemistry, Antalya Education and Research Hospital) ;
  • Gunduz, Seyda (Department of Medical Oncology, Antalya Education and Research Hospital)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Intraperitoneal spread of gynecologic cancers is a major cause of mortality and morbidity and often presents with malignant ascites. Microscopic tumor spread can be demonstrated by a peritoneal wash cytology and help assess the prognosis of the disease. In our study, the roles of paraoxonase and ceruloplasmin, measured in peritoneal washing fluid of patients operated for gynecologic pathologies in differential diagnosis was investigated. Materials and Methods: Patients operated for malign or benign gynecologic pathologies in Antalya Education and Research Hospital Gynecology Clinic between 2010-2012 were included in the study. Samples were obtained during surgery. Results: A statistically significant difference was detected between patients with benign and malign diseases with regards to PON1 levels measured in peritoneal washing fluid (p:0.044), the average values being $64.2{\pm}30.8$ (Range 10.8-187.2) and $41.4{\pm}21.4$ (Range 10.4-95.5), respectively. No significant variation was evident for ceruloplasmin. Conclusions: Paraoxonase levels measured in peritoneal washing fluid may contribute to the differentiation of malign-benign diseases in gynecologic pathologies.

Keywords

References

  1. Ahn JM, Sung HJ, Yoon YH, et al (2013). Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol Cell Proteomics.
  2. Akcay MN, Polat MF, Yilmaz I, Akcay G (2003). Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology, 50, 225-7.
  3. Akcay MN, Polat MF, Yilmaz I, Akcay G (2003). Serum paraoxonase levels in gastric cancer. Hepatogastroenterology, 50, 273-5
  4. Anastasiadis P, Koutlaki N, Liberis V, et al (2011). The contribution of rapid intraoperative cytology in the evaluation of endometrial cancer spread. Ann Acad Med Singapore, 40, 80-3.
  5. Arpaci A, Gormus U, Dalan B, Berkman S, Isbir T (2009). Investigation of PON1 192 and PON1 55 polymorphisms in Ovarian Cancer Patients in Turkish Population. In Vivo, 23, 421-4.
  6. Arumanayagam M, Wong FW, Rogers M, Swaminathan R (1993). Serum ceruloplasmin, plasma copper concentration and copper to ceruloplasmin ratio in cervical carcinoma. Gynecol Obstet Invest, 35, 175-8. https://doi.org/10.1159/000292694
  7. Bobin-Dubigeon C, Jaffre I, Joalland MP, et al (2012). Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence. Clin Biochem, 45, 1503-5. https://doi.org/10.1016/j.clinbiochem.2012.05.021
  8. Camuzcuoglu H, Arioz DT, Toy H, et al (2009). Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol, 112, 481-5. https://doi.org/10.1016/j.ygyno.2008.10.031
  9. Canales A, Sanchez-Muniz FJ (2003). Paraoxanase, something more than an enzyme? Med Clin, 121, 537-48. https://doi.org/10.1016/S0025-7753(03)74011-1
  10. Delimaris I, Faviou E, Antonakos G, et al (2007). Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem, 40, 1129-34. https://doi.org/10.1016/j.clinbiochem.2007.06.007
  11. Eckerson HW, Romson J, Wyte C, La Du BN (1983). The human serum paraoxonase polymorphism: identification of Phenotypes by their response to salts. Am J Hum Genet, 35, 214-27.
  12. Elkiran ET, Mar N, Aygen B, et al (2007). Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer, 7, 48. https://doi.org/10.1186/1471-2407-7-48
  13. Khersonsky O, Tawfik DS (2005). Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry, 44, 6371-82. https://doi.org/10.1021/bi047440d
  14. Kokouva M, Koureas M, Dardiotis E, et al (2013). Relationship between the paraoxonase 1 (PON1) M55L and Q192R polymorphisms and lymphohaematopoietic cancers in a Greek agricultural population. Toxicology, 307, 12-6. https://doi.org/10.1016/j.tox.2012.07.003
  15. Kosaka T, Yamaguchi M, Motomura T, Mizuno K (2005). Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta, 359, 156-62. https://doi.org/10.1016/j.cccn.2005.03.046
  16. Krzystek-Korpacka M, Boehm D, Matusiewicz M, et al (2008). Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromesconnection with inflammation. Clin Biochem, 41, 804-11. https://doi.org/10.1016/j.clinbiochem.2008.03.012
  17. La Du BN, Piko JI, Eckerson HW, Vincent-Viry M, Siest G (1986). An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism. Ann Biol Clin, 44, 369-72.
  18. La Du BN, Aviram M, Billecke S, et al (1999). On the physiological role(s) of the paraoxonasese. Chem Biol Interac, 119-120, 379-88. https://doi.org/10.1016/S0009-2797(99)00049-6
  19. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA (2001). Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affect-ing individual sensitivity to environmental chemicals. Drug Metab Dispos, 29, 566-9.
  20. Macharia M, Hassan MS, Blackhurst D, Erasmus RT, Matsha TE (2012). The growing importance of PON1 in cardiovascular health: a review. J Cardiovasc Med (Hagerstown), 13, 443-53. https://doi.org/10.2459/JCM.0b013e328354e3ac
  21. Mathur V, John PJ, Soni I, Bhatnagar P (2008). Blood levels of organochlorine pesticide residues and risk of reproductive tract cancer among women from Jaipur, India. Adv Exp Med Biol, 617, 387-94. https://doi.org/10.1007/978-0-387-69080-3_37
  22. Ng CJ, Shih DM, Hama SY, et al (2005). The paraoxonase gene family and atherosclerosis. Free Radic Biol Med, 38, 153-63. https://doi.org/10.1016/j.freeradbiomed.2004.09.035
  23. Nowak M, Wielkoszynski T, Marek B, et al (2010). Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med, 10, 185-92. https://doi.org/10.1007/s10238-009-0084-7
  24. Ozyilkan O, Baltali E, Ozyilkan E, et al (1992). Ceruloplasmin level in women with breast disease. Preliminary results. Acta Oncol, 31, 843-6. https://doi.org/10.3109/02841869209089716
  25. Ray G, Batra S, Shukla NK, et al (2000). Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat, 59, 163-70. https://doi.org/10.1023/A:1006357330486
  26. Sankaranarayanan R, Ferlay J (2006). Worldwide burd of gynaecological cancer; the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25. https://doi.org/10.1016/j.bpobgyn.2005.10.007
  27. Sarkar M, Konar H, Raut DK (2012). Gynecological malignancies: epidemiological characteristics of the patients in a tertiary care hospital in India. Asian Pac J Cancer Prev, 13, 2997-3004. https://doi.org/10.7314/APJCP.2012.13.6.2997
  28. Sathiakumar N, MacLennan PA, Mandel J, Delzell E (2011). A review of epidemiologic studies of triazine herbicides and cancer. Crit Rev Toxicol, 41, 1-34.
  29. Senra Varela A, Lopez Saez JJ, Quintela Senra D (1997). Serum ceruloplasmin as a diagnostic marker of cancer. Cancer Lett, 121, 139-45. https://doi.org/10.1016/S0304-3835(97)00340-6
  30. Selvaggi SM (2003). Diagnostic pitfalls of peritoneal washing cytology and the role of cell blocks in their diagnosis. Diagn Cytopathol, 28, 335-41. https://doi.org/10.1002/dc.10290
  31. Sharifi S, Ducatman BS, Wang HH, Fraser JL (1999). Peritoneal washing cytology is unnecessary in gynecologic surgery for benign diseases. Cancer, 87, 259-62. https://doi.org/10.1002/(SICI)1097-0142(19991025)87:5<259::AID-CNCR4>3.0.CO;2-O
  32. Shield P (2004). Peritoneal washing cytology. Cytopathology, 15, 131-41. https://doi.org/10.1111/j.1365-2303.2004.00140.x
  33. Stevens VL, Rodriguez C, Talbot JT, et al (2008). Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Prostate, 68, 1336-40. https://doi.org/10.1002/pros.20796
  34. Vaidya SM, Kamalakar PL (1998). Copper and ceruloplasmin levels in serum of women with breast cancer. Indian J Med Sci, 52, 184-7.
  35. Yildirim M, Karakilinc H, Yildiz M, et al (2013). Non-hodgkin lymphoma and pesticide exposure in Turkey. Asian Pac J Cancer Prev, 14, 3461-3. https://doi.org/10.7314/APJCP.2013.14.6.3461
  36. Zhou ZJ, Zheng J, Wu QE, Xie F (2007). Carboxylic esterase and its associations with long-term effects of organophosphorus pesticides. Biomed Environ Sci, 20, 284-90.
  37. Zuna RE, Behrens A (1996). Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J Natl Cancer Inst, 88, 980-7. https://doi.org/10.1093/jnci/88.14.980